Royal Peptides products are offered exclusively for laboratory research, analytical, and scientific applications. Not for human or veterinary use.
01Research Product Information
Royal Peptides supplies compounds intended for controlled laboratory research and analytical applications.
- For research and analytical use only
- Not intended for human consumption or administration
- Not intended for veterinary use
- Not represented as a drug, medicine, or therapeutic product
- Laboratory researchers are responsible for appropriate protocols and controls
02Lyophilized Product Format
Where applicable, Royal Peptides research materials are supplied in lyophilized form.
Lyophilization is a freeze-drying process used to remove moisture from material under controlled conditions.
- Material appearance may differ between compounds and production lots
- Lyophilized material may appear as a cake, film, or fragmented material
- The quantity of visible material may appear small relative to vial size
- Visual appearance alone does not establish identity or purity
03Storage & Laboratory Handling
Storage requirements may vary by compound, formulation, and production lot. Refer to the product label and available product-specific documentation.
- Protect research materials from excessive heat
- Limit unnecessary exposure to direct light and moisture
- Keep containers securely closed when stored
- Follow product-specific temperature requirements when provided
- Use appropriate laboratory contamination-control procedures
04Packaging & Quality Documentation
Packaging components may vary slightly between production lots. This can include vial closures, cap styles, label positioning, and external packaging.
- Check the product label and lot identifier before laboratory use
- Inspect the vial and closure for visible shipping damage
- Packaging design may differ between batches
- Lot-specific analytical documentation may be available in our COA library
Cartalax Bioregulator Kit
Cartalax Bioregulator – Cartalax 20mg — AED Peptide Bioregulator Research Dossier
Order Cartalax Bioregulator directly from Royal Peptides: Cartilage Research Peptide Kit, lot-tested before release. Cartalax is a tripeptide bioregulator studied in cartilage and connective-tissue models. For repair-focused research, the usual companions are BPC-157 and TB-500, available together as a bpc-157 & tb-500 blend for sale.
Cartalax 20mg is a research-grade short peptide bioregulator identified by the amino-acid sequence Ala-Glu-Asp (AED) and also referenced as T-31. This compact tripeptide has been investigated in experimental research involving cartilage-associated cellular pathways, chondrogenic differentiation, mesenchymal stem cells, extracellular matrix biology, cellular aging and peptide-mediated gene regulation.
Research Use Only
Not for human or veterinary use, administration, ingestion, injection, compounding, diagnostic, therapeutic, clinical, or personal use.
Order Online
Buy Cartalax Bioregulator Online
Pick your strength with the selector at the top of this page and add Cartalax Bioregulator to your cart. Prices are per vial or per kit as shown, and every order ships with lot documentation.
Need larger quantities of Cartalax? Kits and wholesale boxes lower the unit price; see our peptides wholesale usa options.
01
What Is Cartalax Peptide?
Cartalax peptide is a synthetic short-chain tripeptide consisting of alanine, glutamic acid and aspartic acid. It belongs to the broader class of compounds commonly described as short peptide bioregulators.
Ala–Glu–Asp • AED
Cartalax is notable for its compact molecular structure. While many research peptides contain considerably longer amino-acid chains, Cartalax consists of only three amino-acid residues.
Short peptide sequences such as AED have attracted scientific interest in experimental research examining cellular signaling, differentiation, gene expression and tissue-associated regulatory processes.
The AED peptide sequence is also referenced in peptide-bioregulator research by the designation T-31.
02
Cartalax Peptide Research Areas
Research involving Cartalax and the Ala-Glu-Asp peptide has focused primarily on experimental cellular and molecular models.
Cartilage Biology
AED has been investigated in experimental models involving cartilage-associated cellular pathways, chondrogenic differentiation and cartilage matrix biology.
Mesenchymal Stem Cells
Short regulatory peptides have been examined in models involving replicative aging and differentiation of human mesenchymal stem cells.
Gene Expression
Short peptide bioregulators are investigated for possible interactions with mechanisms involved in gene activity, cellular differentiation and regulatory signaling.
Extracellular Matrix Research
Cartalax-related experimental research includes extracellular matrix biology, matrix-associated protein expression and connective-tissue cellular processes.
03
Cartalax and Chondrogenic Research
One area of scientific interest surrounding Cartalax AED peptide research involves chondrogenic differentiation and cartilage-associated cellular pathways.
Experimental research involving short peptides has examined changes in gene and protein expression associated with the differentiation of mesenchymal stem cells toward cartilage-associated cellular phenotypes.
Research in these experimental models has evaluated cartilage-associated markers including SOX9, aggrecan, type II collagen and cartilage oligomeric matrix protein (COMP).
Research Context These findings relate to experimental research models and should not be interpreted as evidence that Cartalax repairs cartilage, restores joints or treats a medical condition.
04
Cartalax as a Short Peptide Bioregulator
Cartalax belongs to a research category commonly referred to as peptide bioregulators. These compounds generally consist of unusually short amino-acid sequences and have been investigated in experimental models involving tissue-associated cellular regulation.
Because Cartalax contains only three amino acids, researchers can investigate a precisely defined molecular sequence when examining hypotheses involving short-peptide signaling, cellular differentiation and gene-expression processes.
Research into short peptide bioregulators remains an evolving field. Findings observed in experimental or cell-culture models cannot automatically be extrapolated to clinical effects.
05
Cartalax AED vs Epitalon AEDG
Cartalax is sometimes confused with Epitalon (Epithalon) because their amino-acid sequences are closely related. They are nevertheless chemically distinct research peptides.
Ala-Glu-AspAED Three amino-acid residues.
Ala-Glu-Asp-GlyAEDG Four amino-acid residues.
The additional glycine residue in AEDG makes Epitalon structurally distinct from Cartalax. The two sequences should not be treated as interchangeable research materials.
06
Cartalax 20mg Research Specifications
07
Why Is Cartalax Studied?
Scientific interest in Cartalax peptide is partly related to the simplicity of its AED sequence. A compound containing only three amino-acid residues provides researchers with a compact model for studying how short peptide sequences may interact with cellular regulatory systems.
Cartalax research therefore intersects with broader investigations into cellular aging, differentiation, extracellular matrix biology, connective-tissue models and gene regulation.
The evidence base for Cartalax remains more limited than for many extensively characterized research peptides. Additional independent replication and mechanistic research remain important.
08
Cartalax Peptide FAQ
What is Cartalax peptide?
Cartalax is a short synthetic tripeptide commonly identified as Ala-Glu-Asp (AED) or T-31 and studied within the broader field of short peptide bioregulator research.
What is the Cartalax peptide sequence?
The Cartalax peptide sequence is Ala-Glu-Asp, abbreviated AED. It contains alanine, glutamic acid and aspartic acid.
What is Cartalax researched for?
Experimental research involving AED has included cartilage-associated cellular pathways, chondrogenic differentiation, mesenchymal stem cells, extracellular matrix biology, cellular aging and gene-expression processes.
Is Cartalax a peptide bioregulator?
Cartalax is commonly categorized within short peptide bioregulator research. Its AED sequence contains three amino-acid residues.
Is Cartalax the same as Epitalon?
No. Cartalax is AED (Ala-Glu-Asp), while Epitalon is AEDG (Ala-Glu-Asp-Gly). They are distinct peptide sequences.
How many amino acids are in Cartalax?
Cartalax contains three amino-acid residues, making it a tripeptide.
What does AED mean in Cartalax?
AED represents the one-letter amino-acid abbreviations for alanine (A), glutamic acid (E) and aspartic acid (D).
Is Cartalax approved for human use?
No. Cartalax is an experimental research compound and is not an approved medication. It is supplied strictly for laboratory research purposes.
Quality Documentation
Cartalax Bioregulator Lot Testing & COA
Every Cartalax Bioregulator lot is independently tested before release; results are listed with our coa tested peptides. For background reading, see published Cartalax research on PubMed.
Related Research
Researchers Also Order
Compounds often studied alongside Cartalax:
Buying Questions
Buying Cartalax Bioregulator
Where can I buy Cartalax Bioregulator?
Order Cartalax Bioregulator directly from Royal Peptides. Choose a format in the Buy section, check out securely and your order ships from U.S. stock with lot documentation.
How fast do orders ship?
Orders are dispatched from U.S. inventory, usually within one business day, with tracking.
Cartalax for Laboratory Research
Cartalax Bioregulator is supplied for laboratory research use only. Not for human or veterinary use.
Specifications
Product information pulled directly from WooCommerce.
COA / Testing
Review available analytical documentation for the applicable product and batch in the COA library.
View COA LibraryShipping & Storage
Shipping options and delivery estimates are shown at checkout. Refer to the product label for storage requirements.
